Takeda’s Entyvio and Janssen’s Stelara Share of Inflammatory Bowel Disease Biologic-Naive Patients Continues to Increase as This Patient Group Expands Their Involvement in the Decision-Making Process
A newly published report by Spherix Global Insights includes the responses of 218 gastroenterologists and 1,001 audited patient records and reveals the current treatment approach for new start ulcerative colitis and Crohn’s disease patients EXTON, Pa., July 30, 2020 /PRNewswire/ — The 2020 audit included in Spherix’s RealWorld Dynamix™: Biologic/Small Molecule New Starts in IBD (US) service […]
Alternate Mechanism Biologics and Adalimumab Biosimilar Prescribing Increases at the Expense of AbbVie’s Humira in the EU5 Inflammatory Bowel Disease Market, Despite the Significant Impact of COVID-19 on Gastroenterology Practitioners
Use of alternative mechanism of action therapies, Janssen’s Stelara and Takeda’s Entyvio, along with adalimumab biosimilars, has increased in the EU5 since last year in ulcerative colitis and Crohn’s disease, according to a recently published study by Spherix Global Insights EXTON, Pa., July 20, 2020 /PRNewswire/ — According to the latest report published as part of […]
Treatment of Anemia Among Hematology/Oncology Specialists Spans Diverse Patient Types, Many of Which Have Multiple Contributory Factors
According to Spherix Global Insights, the potential approval of the hypoxia-inducible factors prolyl-hydroxylase inhibitors could alter referral and treatment patterns for patients with anemia of chronic kidney disease being managed by hematologists/oncologists. EXTON, Pa., July 14, 2020 / PRNewswire / – Spherix recently fielded a survey of 152 hematologists/oncologists in the US in order to […]
COVID-19 Continues to Disrupt Patient Care Among Specialty Physicians, Though There Are Early Signs That Recovery is on the Horizon
According to Spherix Global Insights, just one-tenth of specialty physician offices are operating at normal capacity, and doctors report facing multiple challenges with re-opening EXTON, Pa., July 6, 2020 / PRNewswire / – Results from the seventh wave of an ongoing study examining the impact of COVID-19 on specialty physician practices were released last week […]
Massive Shift in Practice Patterns in Psoriatic Arthritis as Rheumatologists Lean Toward Increased Use of JAK inhibitors and Novel Biologics
Spherix Global Insights releases fifth annual patient chart study focused exclusively on biologic and small molecule switching patterns among US rheumatologists EXTON, Pa., July 2, 2020 /PRNewswire/ – Over the past four years, multiple new agents have been FDA approved for the treatment of psoriatic arthritis (PsA), including Pfizer’s Xeljanz, Eli Lilly’s Taltz, BMS’ Orencia, […]
While Gilead/Galapagos’ Filgotinib Will Have to Contend with the Early Success of AbbVie’s Rinvoq in the US Rheumatoid Arthritis Market, Eli Lilly’s Olumiant is Likely to be the More Formidable Foe in the EU
A stark contrast in use and preference of the JAK inhibitors between the two regions sets varying competitive landscapes for pipeline agents in rheumatoid arthritis EXTON, Pa., July 1, 2020 / PRNewswire / – Analysis of the most recent semiannual report included in Spherix’s RealTime Dynamix™: Rheumatoid Arthritis (EU) service, which captured the responses of […]
Eli Lilly’s Reyvow Struggles to Gain Ground in the Acute Segment of the US Migraine Market, Overshadowed by AbbVie’s Ubrelvy and Biohaven’s Nurtec ODT, According to Spherix Global Insights
Lilly could build upon their existing payer relationships to construct favorable migraine portfolio contracting and position Reyvow as the preferred acute treatment for patients concurrently treated with calcitonin gene-related peptide monoclonal antibodies – a growing segment of the population EXTON, Pa., June 30, 2020 /PRNewswire/ — The number of companies active in the migraine space […]
EU5 Rheumatologists Expect the Introduction of Janssen’s Tremfya in Psoriatic Arthritis to Blunt Anticipated Growth of Eli Lilly’s Taltz, Novartis’ Cosentyx, and Pfizer’s Xeljanz
A new independent study conducted by Spherix Global Insights reveals projected erosion of branded TNF inhibitors and stabilization of biosimilars and alternate mechanism agents resulting from the introduction of the next likely entrant in the EU5 psoriatic arthritis market EXTON, Pa., June 23, 2020 / PR Newswire / – Spherix recently published the inaugural report […]
Nephrologists Are Hesitant to Fully Embrace Janssen’s INVOKANA Despite Being the First and Only SGLT2 Inhibitor with an FDA Indication to Treat Diabetic Kidney Disease
According to Spherix Global Insights’ latest quarterly survey of 101 US nephrologists, despite anticipated increases in use, over one-third of respondents still express some trepidation in prescribing INVOKANA EXTON, Pa., June 18, 2020 / PR Newswire / – Millions of patients across the United States suffer from Type 2 diabetes, and one-quarter or more of […]
Bristol Myers Squibb’s Zeposia and Janssen’s Ponesimod Could Be Early-Line Winners, While Biogen’s Vumerity Appears Relegated to Tolerability Switches Within the Fumarate Class
Current competition among the high-efficacy oral and monoclonal antibody therapies has done little to thwart growth of Genentech’s Ocrevus, but Novartis’ ofatumumab may have what it takes, according to Spherix Global Insights EXTON, Pa., June 16, 2020 /PRNewswire/ —Neurologist-reported treatment patterns in multiple sclerosis (MS) reveal a continued trend of using more high-efficacy disease-modifying therapies […]
